B
Bull
Bull · 25%PTIX
$4.08
Szenariopreis
$0.740
-0.319 (-43.08%)Zum Schluss
Loading chart…
- High
- 1.270
- Open
- 1.260
- VWAP
- 0.90
- Vol
- 1.92M
- Mkt Cap
- 4.01M
- Low
- 0.702
- Amount
- 1.74M
- EV/EBITDA, TTM
- 0.00
Protagenic Therapeutics, Inc. is a neuroactive biopharmaceutical company. The Company has approximately six drug candidates targeting stress-related and CNS disorders, including treatments for obesity and metabolic disorders. The Company's pipeline includes PT-00114 in Phase I/IIa and five preclinical assets including PHYX-001, cannabinoid-based compounds, and modified stilbenoid assets. The PHYX-001 is a potassium channel modulator with a mechanism similar to XEN1101 and BHV-7000. The Company's cannabinoid assets include multiple cannabinoid-based compounds with composition-of-matter IP; potential in CNS, cardiometabolic, and other indications. The Company's cannabinoid assets also include a molecule with potential in the obesity, metabolic dysfunction sector, where the GLP-1 agonists have become medications. Its modified stilbenoid assets include modified stilbenoid compounds with composition-of-matter IP and anticonvulsant activity in preclinical models.
Bewertungskennzahlen
The current forward P/E ratio for Protagenic Therapeutics Inc (PTIX) is -0.10, compared to its 5-year average forward P/E of -2.39.
Alphio AI Price Scenarios for PTIX
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
7.011-27SeekingAlphaProtagenic Therapeutics issued a letter regarding Nasdaq non-compliance
- 7.008-22SeekingAlpha
Protagenic Therapeutics Announces Timeline for Form 10-Q Filing and Nasdaq Compliance Update
9.008-21BenzingaProtagenic Therapeutics (PTIX) Stock Rises Following Advancements in Clinical Trials
4.508-21BenzingaS&P 500 Declines; Walmart Stock Drops Following Q2 Earnings Report
4.508-21BenzingaDow Falls by More Than 100 Points as US Initial Jobless Claims Rise
PTIX FAQ — answered by Alphio AI
Protagenic Therapeutics, Inc. is a neuroactive biopharmaceutical company. The Company has approximately six drug candidates targeting stress-related and CNS disorders, including treatments for obesity and metabolic disorders. The Company's pipeline includes PT-00114 in Phase I/IIa and five preclinical assets including PHYX-001, cannabinoid-based compounds, and modified stilbenoid assets. The PHYX-001 is a potassium channel modulator with a mechanism similar to XEN1101 and BHV-7000. The Company's cannabinoid assets include multiple cannabinoid-based compounds with composition-of-matter IP; potential in CNS, cardiometabolic, and other indications. The Company's cannabinoid assets also include a molecule with potential in the obesity, metabolic dysfunction sector, where the GLP-1 agonists have become medications. Its modified stilbenoid assets include modified stilbenoid compounds with composition-of-matter IP and anticonvulsant activity in preclinical models. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.